

# **PUBLICATIONS**

## **Maija Itälä-Remes**

### **Original articles**

1. **Itälä M**, Helenius H, Nikoskelainen J, Remes K. Infections and serum IgG levels in patients with chronic lymphocytic leukemia. *Eur J Haematol* 1992; 48: 266-270.
2. **Itälä M**, Viikari J. Toistuvat tajuttomuuskohtaukset. *Duodecim* 1993; 109: 1428-32.
3. **Itälä M**, Pelliniemi T-T, Remes K. GM-CSF raises serum levels of beta-2-microglobulin and thymidine kinase in patients with chronic lymphocytic leukaemia. *Br J Haematol* 1996; 94: 129-132.
4. **Itälä M**, Vainio O, Remes K. Functional abnormalities in granulocytes predict susceptibility to bacterial infections in chronic lymphocytic leukaemia. *Eur J Haematol* 1996; 57: 46-53.
5. **Itälä M**, Remes K. The COP regimen is not a feasible treatment for advanced, refractory chronic lymphocytic leukaemia. *Leuk Lymphoma* 1996; 23: 137-141.
6. **Itälä M**, Vanhatalo S, Remes K. Effect of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) on chemotherapy-induced myelosuppression in patients with chronic lymphocytic leukaemia. A cross-over study. *Leuk Lymphoma* 1997; 25: 503-508.
7. **Itälä M**, Kotilainen P, Nikkari S, Remes K, Nikoskelainen J. Pure red cell aplasia caused by B19 parvovirus infection after autologous blood stem cell transplantation in a patient with chronic lymphocytic leukaemia. *Leukemia* 1997; 11: 171.
8. Remes K, Matinlauri I, Grenman S, **Itälä M**, Kauppila M, Nikoskelainen J, Pelliniemi T-T, Salminen E, Vanharanta-Hiltunen R, Rajamäki A. Daily measurements of blood CD34+ cells after stem cell mobilization predict stem cell yield and post-transplant hematopoietic recovery. *J Hematother* 1997; 6: 13-19.
9. **Itälä M**, Pelliniemi T-T, Rajamäki A, Remes K. Autologous blood stem cell transplantation in B-CLL: response to chemotherapy prior to mobilization predicts the stem cell yield. *Bone Marrow Transplant* 1997; 19: 647-651.
10. **Itälä M**. Kroonisen lymfaattisen leukemian nykyhoito. *Duodecim* 1997; 113: 1015-1022.
11. Remes K, Rajamäki A, Grenman S, **Itälä M**, Kauppila M, Nikoskelainen J, Pelliniemi T-T, Ristamäki R, Salmi Toivo T, Salmi T, Salminen E, Vanharanta R, Toivanen A. Autologinen kantasolusiirto – luuytimensiirrosta veren kantasolujen siirtoon syövän intensiivihoidossa. Kokemukset ensimmäisten 100 potilaan autologisista kantasolusiirroista. *Duodecim* 1997; 113: 219-228.
12. **Itälä M**, Pelliniemi T-T, Remes K. Long-term treatment with GM-CSF in patients with chronic lymphocytic leukaemia and recurrent neutropenic infections. *Leuk Lymphoma* 1998; 32: 165-174.
13. **Itälä M**. Ensimmäinen syövän hoitoon hyväksytty monoklonaalinen vasta-aine. *Duodecim* 1998; 114: 509-511.

14. **Itälä M.** Käytännön näkökohtia antikoagulanttihoidosta. *Erikoislääkäri* 1998; 5: 233-238.
15. Grenman S, Remes K, Inki P, **Itälä M**, Kauppila M, Pelliniemi T-T, Rajamäki A, Rantanen M, Salmi TT, Vuento M, Salmi T. Kokemukset 10 ensimmäisen munasarjasyöpäpotilaan suuriannoksisesta solunsalpaajahoidosta Turussa. *Suom Lääk L* 1999; 54: 3359-64.
16. Hohenthal U, Nikoskelainen J, Vainionpää R, Peltonen R, Routamaa M, **Itälä M**, Kotilainen P. Parainfluenza virus type 3 infections in a hematology unit. *Bone Marrow Transplant* 2001; 27: 295-300.
17. **Itälä M**, Remes K. Nukleosidianalogit - uusia lääkkeitä lymfaattisten syöpien hoitoon. *Duodecim* 2001; 117: 162-169.
18. Hietarinta M, **Itälä M**, Kauppila M, Koskela K. Tapausselostus: Miksi nuori mies sai toistuvan keuhkoembolian ? *Duodecim* 2001; 117: 578-80.
19. Hohenthal U, Nikoskelainen J, Vainionpää R, Peltonen R, Routamaa M, **Itälä M**, Kotilainen P. Human parainfluenza type 4 virus (hPIV4) infection provoking many questions regarding the role of this virus as the causative agent of respiratory tract infections in the post-transplant setting. *Bone Marrow Transplant* 2002; 29: 629-30.
20. Oinonen R, Jantunen E, **Itälä M**, Lehtinen T, Kuittinen O, Franssila K, Wiklund T ja Elonen E. Autologous stem cell transplantation in patients with mantle cell lymphoma. *Leuk Lymphoma* 2002; 43: 1229-37.
21. **Itälä M**, Geisler CH, Kimby E, Juvonen E, Tjonnfjord G, Karlsson K, Remes K. Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study. *Eur J Haematol* 2002; 69: 129-34.
22. **Itälä M.** Krooninen lymfaattinen leukemia. *Focus Oncologiae* 2002; 3: 52-6.
23. **Itälä M.** Monoklonaaliset vasta-aineet hematologisten syöpien hoidossa. *Duodecim* 2002; 118: 1647-56.
24. Remes K, **Itälä M**, Kauppila M, Pelliniemi T-T, Rajamäki A. Autologous blood cell transplantation in multiple myeloma: impact of CD34+ cell selection with long follow-up. *J Hematol Stem Cell* 2003; 12: 63-70.
25. **Itälä M**, Remes K. Excellent response of refractory life-threatening thrombotic thrombocytopenic purpura. *Clin Lab Haem* 2004; 26: 1-3.
26. **Itälä M**, Remes K. Reduced-intensity conditioning and blood stem cell transplantation from a HLA-identical sibling for severe aplastic anaemia: two patients with successful engraftment but a fatal post-transplant lymphoproliferative disorder in the other. *Hematol J* 2004.
27. Jantunen E, Salonen J, Juvonen E, Koivunen E, Siitonen T, Lehtinen T, Kuittinen O, Leppä S, Anttila V-J, **Itälä M**, Wiklund T, Remes K, Nousiainen T. Invasive fungal infections in autologous stem cell transplant recipients: a nationwide study of 1188 transplanted patients. *Eur J Haematol* 2004; 73: 174-178.
28. Virtanen R, Kauppila M, **Itälä M.** Percutaneous coronary intervention with stenting in a patient with haemophilia A and an acute myocardial infarction following a single dose desmopressin. *Thromb Haemostasis* 2004; 92: 1154-6.

29. Hohenthal U, **Itälä M**, Salonen J, Sipilä J, Rantakokko-Jalava K, Meurman O, Nikoskelainen J, Vainionpää R, Kotilainen P. Bronchoalveolar lavage in haematological patients with clinical pneumonia – value of new microbiological methods. *Eur J Haematol* 2004.
30. Putkonen M, Rauhala A, **Itälä M**, Kauppila M, Pelliniemi T-T, Remes K. Double vs single autotransplantation in multiple myeloma; single center experience of 100 patients. *Hematol J* 2005.
31. **Itälä M**. B-cell chronic lymphocytic leukaemia and increased susceptibility to infections. Academic dissertation, Turku 1996.
32. Jantunen E, **Itälä M**, Lehtinen T, Kuittinen O, Koivunen E, Leppä S, Juvonen E, Koistinen P, Wiklund T, Nousiainen T, Remes K, Volin L. Early treatment-related mortality in adult autologous stem cell transplant recipients: a nation-wide survey of 1482 transplanted patients. *Eur J Haematol*. 2006; 76(3): 245-50.
33. Jantunen E, **Itälä M**, Lehtinen T, Kuittinen O, Koivunen E, Leppä S, Juvonen E, Koistinen P, Wiklund T, Nousiainen T, Remes K, Volin L. Autologous stem cell transplantation in elderly (>60 years) patients with non-Hodgkin's lymphoma: a nation-wide analysis. *Bone Marrow Transplant*. 2006; 37(4): 367-72.
34. Grenman S, Wiklund T, Jalkanen J, Kuoppala T, Mäenpää J, Kuronen A, Leminen A, Puistola U, Vuolo-Merilä P, Salmi T, Vuento M, Yliskoski M, **Itälä M**, Helenius H, Joensuu H, Lehtovirta P. A randomized phase III study comparing high-dose chemotherapy to conventionally dosed chemotherapy for stage III ovarian cancer. The Finnish ovarian cancer (FINOVA) study. *European Journal of Cancer* 2006; 42: 2196-2199.
35. Jantunen E, **Itälä M**, Lehtinen T, Kuittinen O, Koivunen E, Leppä S, Juvonen E, Koistinen P, Wiklund T, Nousiainen T, Remes K, Volin L. Late non-relapse mortality among adult autologous stem cell transplant recipients: a nation-wide analysis of 1482 patients transplanted in 1990-2003. *Eur J Haematol* 2006; 77: 114-9.
36. Jantunen E, **Itälä M**, Lehtinen T, Kuittinen O, Koivunen E, Leppä S, Juvonen E, Koistinen P, Wiklund T, Nousiainen T, Remes K, Volin L. Autologous stem cell transplantation in patients with chronic lymphocytic leukaemia: the Finnish experience. *Bone Marrow Transplant* 2006; 37:1093-8.
37. Koistinen P, Rätty R, **Itälä M**, Jantunen E, Koivunen E, Nousiainen T, Pelliniemi T-T, Remes K, Ruutu T, Savolainen E-R, Siitonen T, Silvennoinen R, Volin L, Elonen E for the Finnish Leukaemia Group. Intensive chemotherapy in adult acute myeloid leukaemia (AML): outcome of the Finnish nationwide AML-92 study. *Eur H Haematol* 2007; 78: 477-486.
38. Sivula J, Volin L, Porkka K, Vettenranta K, **Itälä M**, Partanen J, Turpeinen H. Natural killer cell KIR-ligand compatibility and outcome of unrelated donor hematopoietic stem cell transplantation. *Transplant Immunol* 2007; 18(1): 62-6.
39. Sinisalo M, Vilpo J, **Itälä M**, Väkeväinen M, Taurio J, Aittoniemi J. Antibody response to 7-valent conjugated pneumococcal vaccine in patients with chronic lymphocytic leukemia. *Vaccine* 2007; 26(1): 82-7.
40. Jantunen E, **Itälä M**, Siitonen T, Kuittinen T, Heiskanen J, Koivunen E, Juvonen E, Silvennoinen R, Nousiainen T, Koistinen P, Volin L, Remes K. Progenitor cell mobilisation and collection in patients with chronic lymphocytic leukaemia: a nation-wide analysis. *Bone Marrow Transplant* 2008; 41(3): 239-44.

41. **Itälä M**, Huhtinen A-R, Juvonen V, Kairisto V, Pelliniemi T-T, Penttilä T-L, Rauhala A, Tienhaara A, Remes K. Stem cell transplantation in poor-risk chronic lymphocytic leukemia: assessment of posttransplant minimal residual disease using four- six-color flow cytometry and allele-specific RQ-PCR. *Eur J Haematol* 2008; 81(2): 100-6.
42. Schetelig J, van Biezen A, Brand R, Caballero D, Martino R, **Itälä M**, Garcia-Marco J-A, Volin L, Schmitz N, Schwerdtweger R, Ganser A, Onida F, Mohr B, Stilgenbauer S, Bornhäuser M, de Witte T, Dreger P. Allogeneic hematopoietic cell transplantation for chronic lymphocytic leukaemia with 17p deletion: a retrospective EBMT analysis. *J Clin Oncol* 2008.
43. Airas L, **Itälä M**, Remes K, Päivärinta M. Central nervous system immune reconstitution inflammatory syndrome (IRIS) after hematopoietic SCT. *Bone Marrow Transplant* 2009 Aug 17.
44. **Itälä-Remes M**. Krooninen lymfaattinen leukemia. *Otteita Lääkärin Käsikirjasta. Duodecim* 2009; 125(16): 1745-8.
45. Putkonen M, Kairisto V, Juvonen V, Pelliniemi TT, Rauhala A, **Itälä-Remes M**, Remes, K. Depth of response assessed by quantitative ASO-PCR predicts the outcome after stem cell transplantation in multiple myeloma. *Eur J Haematol* 2010; 85: 416-23.
46. Syrjälä H, Ohtonen P, Kinnunen U, Rätty R, Elonen E, Nousiainen T, Jantunen E, Remes K, **Itälä-Remes M**, Silvennoinen R, Koistinen P; Finnish Leukemia Group. Blood stream infections during chemotherapy-induced neutropenia in adult patients with acute myeloid leukemia: treatment cycle matters. *Eur J Clin Microbiol Infect Dis* 2010; 29: 1211-8.
47. Sinisalo M, Sankelo M, **Itälä-Remes M**. Thrombopoietin receptor (TPO-R) agonists can be used temporarily with patients suffering from refractory CLL-associated ITP. *Leuk Lymphoma* 2011.
48. Toivari A, **Itälä-Remes M**, Kauppila M, Putkonen M, Salmenniemi U, Remes K. Stem cell transplantation in myelofibrosis. *Duodecim* 2011; 127(22):2375-82.
49. Virtanen JM, Remes K, Itälä-Remes MA, Saunavaara JP, Komu ME, Parkkola RK. The relationship between cardiac and liver iron evaluated by MR imaging in haematological malignancies and chronic liver disease. *Blood Cancer J* 2012; 2(1):e49.
50. Lindström V, Aittoniemi J, Jylhävä J, Hurme M, Paavonen T, **Itälä-Remes M**, Sinisalo M. Indoleamine 2,3-dioxygenase activity and expression in patients with chronic lymphocytic leukaemia. *Clinical Lymphoma, Myeloma & Leukemia* 2012; 12(5): 363-5.
51. Vojdeman FJ, Jurlander J, van't Veer M, **Itälä-Remes M**, Kimby E, Tjønnfjord GE, Walewski J, Kozák T, Polliack A, Montagna M, Regazzi M, Kirkby N, van Putten W, Spoelstra F, van Oers M, Geisler CH. Plasma alemtuzumab levels in CLL patients treated with alemtuzumab combined with chemotherapy reflect the efficacy of the treatment – a hypothesis. *Leuk Lymphoma* 2013; 54(4): 790-3.
52. Salmenniemi U, Remes K, **Itälä-Remes M**. Outcome of allogeneic SCT in patients with pre-transplant invasive fungal infection. *Bone Marrow Transplant* 2013; 48(9): 1262-3.
53. Virtanen J, **Itälä-Remes M**, Remes K, Vahlberg T, Saunavaara JP, Sinisalo M, Parkkola RK. Prognostic impact of pre-transplant iron overload measured with

magnetic resonance imaging on severe infections in allogeneic stem cell transplantation. *Eur J Haematol* 2013; 9(1): 85-93.

54. Geisler CH, van t'Veer MB, Jurlander J, Walewski J, Tjønnfjord G, **Itälä-Remes M**, Kimby E, Wu K, Kozak T, Polliack A, Wittebol S, Alamayahu W, Spoelstra F, van Oers MHJ. HOVON68-CLL: Addition of low-dose alemtuzumab to 1<sup>st</sup>-line therapy with fludarabine and cyclophosphamide (FC) prolongs progression-free survival in high-risk chronic lymphocytic leukaemia. *Blood* 2014; 123(21): 3255-62.
55. Armand P, Kim HT, Virtanen JM, **Itälä-Remes MA**, Majhail NS, Burns LJ, Todd DeFor T, Trottier B, Platzbecker U, Antin JH, Wermke M. Iron overload in allogeneic stem cell transplantation outcome: a meta-analysis. *Biol Blood Marrow Transplant* 2014; 20(8): 1248-51.
56. Kontro M, Kuusanmäki H, Eldfors S, Burmeister T, Andersson EI, Bruserod O, Brümmendorf TH, Edgren H, Gjertsen BT, **Itälä-Remes M**, Lagström S, Lohi O, Lundan T, Marti JM, Majumder MM, Parsons A, Pevomska T, Rajala H, Vettenranta K, Kallioniemi O, Mustjoki S, Porkka K, Heckman CA. Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia. *Leukemia* 2014; 28(8): 1738-42.
57. Nylund R, Itälä-Remes M, Kauko T, Kauppila M, Putkonen M, Salmenniemi U, Salmi T, Remes K. Adult acute lymphoblastic leukemia - 20-year treatment results at TYKS. *Duodecim* 2014; 130(7): 7140-20.
58. Oksman MJ, **Itälä-Remes M**, Kauppila M, Putkonen M, Salmenniemi U, Salmi T, Remes K. Bisphosphonates do not delay engraftment after autologous SCT in patients with newly diagnosed myeloma. *Bone Marrow transplant* 2015; 50(1): 157.
59. Salmenniemi U, Kairisto V, Leino J, Putkonen M, Kauppila M, Salmi T, Oksman M, Remes K, **Itälä-Remes M**. Application of sensitive allele-SEQR chimerism PCR from peripheral blood in allografted AML/MDS patients treated with pre-emptive post-transplant immunomodulation. *J Leuk* 2015; 3: 2.
60. Järvenpää J, **Itälä-Remes M**, Kauko T, Salmenniemi U, Kauppila M, Putkonen M, Salmi T, Remes K. Aikuisten akuutin myeloosien leukemian hoitotulokset Tyksissä 2002–2012. *Duodecim* 2016.
61. Vojdeman FJ, Herman SEM, Kirkby N, Wiestner A, van t' Veer MB, Tjønnfjord GE, **Itälä-Remes M**, Kimby E, Farooqui MZ, Polliack A, Wu KL, Doorduijn J, Alemayehu WG, Wittebo SI, Kozak T, Walewski J, Abrahamse-Testroote MCJ. Soluble CD52 levels mark differential treatment efficacy with chemo-immunotherapy and ibrutinib in patients with CLL Short title for running head: sCD52 marks differential treatment efficacy in CLL. *LeukLymphoma* 2016.
62. Törlén J, Ringdén O, Garming-Legert K, Ljungman P, Winiarski J, Remes K, **Itälä-Remes M**, Remberger M, Mattsson J. A prospective randomized trial comparing tacrolimus/sirolimus vs cyclosporine/methotrexate as GVHD prophylaxis after allogeneic HSCT. *Haematologica* 2016; 101(11):1417.
63. Impola U, Larjo A, Salmenniemi U, Putkonen M, **Itälä-Remes M**, Partanen J. Variation in immune cell composition of stem cell grafts is associated with clinical outcome of allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia. *Frontiers in Immunology* 2016; 7: 523.
64. Vojdeman FJ, van t' Veer MB, Tjønnfjord GE, **Itälä-Remes M**, Kimby E, Polliack A, Wu KL, Doorduijn J, Alemayehu WG, Wittebol S, Kozak T, Walewski J, Abrahamse-Testroote MCJ, van Oers MHJ, Geisler CH. The HOVON68 trial

revisited: Performance status and comorbidity affect survival in elderly patients. *Leuk Lymphoma* 2016.

65. Scheid C, de Wreede L, van Biezen A, Volin L, Maertens J, Finke J, Passweg J, Beelen D, Cornelissen JJ, **Itälä-Remes M**, Chevallier P, Russell N, Petersen E, Milpied N, Espiga CR, Peniket A, Sierra J, Mufti G, Crawley C, Veelken JH, Ljungman P, Cahn JY, Alessandrino EP, de Witte T, Robin M, Kröger N. The Revised IPSS (IPSS-R) At Transplant Predicts Overall and Relapse-Free Survival After Allogeneic Stem Cell Transplantation In myelodysplastic syndrome / transformed acute myelogenous leukemia: A Retrospective Analysis Of The EBMT Chronic Malignancies Working Party. *Bone Marrow transplant* 2017; 52(11): 1519.
66. Salmenniemi U, **Itälä-Remes M**, Nystedt J, Putkonen M, Vettenranta K, Korhonen M. Long-term outcome of the patients with steroid-refractory GVHD treated with unmatched mesenchymal stromal cells. *Bone Marrow Transplant* 2017; 52(4): 606.
67. Martínez C, Gayoso J, Canals C, Finel H, Thomson K, Dominiotto A, Castagna L, Afanasyev B, Robinson S, Blaise D, Corradini P, **Itälä-Remes M**, Conde E, Milpied N, Russo D, Potter M, McQuaker G, Yakoub-Agha I, Scheid C, Bloor A, Montoto S, Dreger P, Sureda A, Lymphoma Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Post-transplant cyclophosphamide-based haploidentical transplantation as alternative to matched sibling or unrelated donor transplantation for Hodgkin lymphoma: a registry study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. *J Clin Oncol* 2017; 35(30): 3425.
68. Pahnke S, Larfors G, Axdorph-Nygell U, Fischer-Nielsen A, Haastrup E, Haldal D, **Itälä-Remes M**, Johansson JE, Kauppila M, Lenhoff S, Niittyvuopio R, Sandstedt A, Hägglund H. Short-term side effects and attitudes towards second donation: a comparison of related and unrelated haematopoietic stem cell donors. *J Clin Apher* 2017.
69. Aarne Kolonen, Marjatta Sinisalo, Reetta Huttunen, Jaana Syrjänen, Janne Aittoniemi, Heini Huhtala, Marja Sankelo, Hannele Rintala, Riikka Rätty, Esa Jantunen, Tapio Nousiainen, Marjaana Säily, Marjut Kauppila, Maija **Itälä-Remes**, Hanna Ollikainen, Auvo Rauhala, Marjaana Säily, Pirjo Koistinen and Erkki Elonen for the Finnish Leukemia Group. Bloodstream infections in acute myeloid leukemia patients treated according to AML-2003 protocol (Finnish Leukemia Group) – a nationwide study between the years 2003 and 2011. *Infect Dis* 2017; 49(11-12): 799.
70. Gagelmann N, Eikema DJ, Iacobelli S, van Biezen A, Koster L, Nahi H, Stoppa AM, Masszi T, Caillot D, Lenhoff S, Udvardy M, Crawley C, Arcese W, Mariette C, Hunter A, Leleu X, Schipperus M, Delforge M, Pioltelli P, Snowden JA, **Itälä-Remes M**, Musso M, Garderet L, Kröger N. Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: A study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. *Haematologica* 2018; 103(5): 890.
71. Lindström V, Aittoniemi J, Salmenniemi U, Käyhty H, Huhtala H, **Itälä-Remes M**, sinisalo M. Long-term persistence of protective antibodies after pneumococcal conjugate vaccination in patients with chronic lymphocytic leukemia. *Human Vaccin Immunother* 2018; 14(6): 1471.
72. Keto J, Kaartinen T, Salmenniemi U, Castrén J, Partanen J, Hänninen A, Korhonen M, Lähteenmäki K, **Itälä-Remes M**, Nystedt J. Immunomonitoring of MSC-treated GvHD patients reveals only moderate potential for response

prediction but indicates treatment safety. *Mol Ther Methods & Clinical Development* 2018; 9: 109.

73. Koskela S, Ritari J, Hyvärinen K, Kwan T, Niittyvuopio R, **Itälä-Remes M**, Pastinen T, Partanen J. Hidden genomic MHC disparity between HLA-matched sibling pairs in hematopoietic stem cell transplantation. *Scientific Reports* 2018.
74. Czerw T, Labopin M, Giebel S, Socie G, Volin L, Fegueux N, Masszi T, Blaise D, Chaganti S, Cornelissen JJ, Passweg J, Maertens J, **Itälä-Remes M**, Wu D, Mohty M, Nagler A. Anti-thymocyte globulin improves survival free from relapse and graft-versus-host disease after allogeneic peripheral blood stem cell transplantation in patients with Philadelphia-negative acute lymphoblastic leukemia: an analysis by the Acute Leukemia Working Party of the EBMT. *Cancer* 2018; 124(12): 2523.
75. Ruggeri A, Labopin M, Bacigalupo A, Afanasyev B, Cornelissen JJ, Elmaagacli A, **Itälä-Remes M**, Blaise D, Meijer E, Koc Y, Milpied N, Schouten HC, Kröger N, Mohty M, Nagler A. Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT. *J Hematol Oncol* 2018; 11(1): 40.
76. Ritari J, Hyvärinen K, Koskela S, Saavalainen P, Niittyvuopio R, Volin L, **Itälä-Remes M**, Pastinen T, Partanen J. Genomics of chronic graft-versus-host disease after hematopoietic stem cell transplantation. *Leukemia* 2018 Aug 8. doi: 10.1038/s41375-018-0229-3. Epub ahead of print.
77. McLornan DP, Szydlo R, Robin M, van Biezen A, Koster L, Blok HJP, Van Lint MT, Finke J, Vitek A, Carlson K, Griskevicius L, Holler E, **Itälä-Remes M**, Schaap M, Socie G, Bay JO, Beguin Y, Bruno B, Cornelissen JJ, Gedde-Dahl T, Ljungman P, Rubio MT, Yakoub-Agha I, Klyuchnikov E, Olavarria E, Chalandon Y, Kröger N. Outcome of patients with myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of EBMT. *Br J Haematol* 2018 May 29. doi: 10.1111/bjh.15407. Epub ahead of print.
78. Martelin E, Volin L, **Itälä-Remes M**, Niittyvuopio R, Lindström V, Heiskanen J, Ruutu T, Nihtinen A. Incidence and risk factors of secondary cancers after allogeneic stem cell transplantation: analysis of a single centre cohort with a long follow-up. *Bone Marrow Transplant* 2018 Aug 13. doi: 10.1038/s41409-018-0290-6. Epub ahead of print.
79. Ranti J, Kurki S, Salmenniemi U., Putkonen M., **Itälä-Remes M**. Early CD8+ reconstitution is an independent predictive factor for lower risk of relapse, but increases risk of severe graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. *PLOS One* 2018.

## **Textbooks**

80. **Itälä M** ja Vilpo J. Kypsäsoluiset krooniset lymfaattiset leukemiat. Veritaudit, toim. Krusius T, Rajamäki A ja Ruutu T, Kustannus Oy Duodecim 2005.
81. **Itälä M**. Krooninen lymfaattinen leukemia. Lääkäriin käsikirja, Kustannus Oy Duodecim 2007

82. Sinisalo M ja **Itälä-Remes M.** Hemolyyttisten kriisien diagnostiikka. Hemolyyttisten kriisien hoito. Akuuttihoito-opas, Kustannus Oy Duodecim 2010 (updated 2018).
83. **Itälä-Remes M.** Transplantaatioimmunologia. Kirjassa Veritaudit. Kust. Duodecim 2015
84. **Itälä-Remes M.** ja Volin L. Kantasolujensiirrot. Kirjassa Veritaudit. Kust. Duodecim 2015

## **Other**

85. **Itälä-Remes M.** ASH 2013 Kokousraportti: Akuutit leukemiat ja allogeeninen kantasolujensiirto (2/2014, Toim Kimmo Porkka, Tarja-Terttu Pelliniemi, Kust. Novartis)
86. **Itälä-Remes M.** ASH 2015 kokousraportti: Allogeeniset luuytimensiirrot (2/2016, Toim Kimmo Porkka, Tarja-Terttu Pelliniemi, Kust. Novartis)
87. **Itälä-Remes M.** Syövän kantasoluhoidot. SIC Fimea 2016.

## **Manuscripts submitted**

1. Cremers EMP, de Witte T, de Wreede L, Eikema D-J, Koster L, van Biezen A, Finke J, Socie G, Beelen D, Maertens J, Nagler A, Kobbe G, Ziagos D, **Itälä-Remes M**, Gedde-Dahl T, Sierra J, Niederwieser D, Ljungman P, Beguin Y, Ozkurt Z, Anagnostopoulos A, Jindra P, Robin M, Kröger N. A prospective non-interventional study on the impact of transfusion and related iron toxicity on outcome in myelodysplastic syndromes undergoing allogeneic haematopoietic cell transplantation. A study on behalf of the MDS subcommittee of the Chronic Malignancies working party of the European Society for Blood and Marrow transplantation. Submitted 2018.
2. Gagelmann N, Eikema DJ, Koster L, Caillot D, Pioltelli P, Ileonart JB, Remenyi P, Blaise D, Schaap N, Trneny M, Passweg J, Porras RP, Cahn JY, Musso M, Poire X, Kobbe G, **Itälä-Remes M**, Pavone V, Fouillard L, Schoemans H, Bron D, Pouli A, Schroyens W, Schönland S, Garderet L, Yakoub-Agha I, Kröger N. Tandem autologous stem cell transplantation improves outcome in newly diagnosed multiple myeloma with extramedullary disease and high-risk cytogenetics: a study from the Chronic Malignancies Working Party of EBMT. Submitted 2018.
3. Catherine J. Lee <sup>1</sup>, Myriam Labopin <sup>2,3</sup>, Dietrich Beelen <sup>4</sup>, Jürgen Finke <sup>5</sup>, Didier Blaise <sup>6</sup>, Arnold Ganser <sup>7</sup>, Maija Itälä-Remes <sup>8</sup>, Patrice Chevallier <sup>9</sup>, Hélène Labussière-Wallet <sup>10</sup>, Johan Maertens <sup>11</sup>, Ibrahim Yakoub-Agha <sup>12</sup>, Jean-Henri Bourhis <sup>13</sup>, Audrey Mailhol <sup>2</sup>, Mohamad Mohty <sup>3</sup>, Bipin N. Savani <sup>14</sup>, and Arnon Nagler <sup>2,15</sup> Comparative Outcomes of Myeloablative and Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Therapy-Related Acute Myeloid Leukemia with Prior Solid Tumor: a report from the ALWP of the EBMT. Submitted 2018.
4. Jonna Clancy<sup>1</sup>, Jarmo Ritari<sup>1</sup>, Muriel Lobier<sup>1</sup>, Riitta Niittyvuopio<sup>2</sup>, Urpu Salmenniemi<sup>3</sup>, Mervi Putkonen<sup>3</sup>, Maija Itälä-Remes<sup>3</sup>, Jukka Partanen<sup>1</sup>, Satu Koskela<sup>1</sup>. Increased MHC matching by C4 gene compatibility in URD HSCT. Submitted 2018

5. Fie J. Vojdeman\*<sup>1</sup>, Lone B. Pedersen<sup>2</sup>, Doreen te Raa<sup>3</sup>, Vesa Juvonen<sup>4</sup>, Yvette van Norden<sup>5</sup>, Geir E. Tjønnfjord<sup>6</sup>, Eva Kimby<sup>7</sup>, Maija Itälä-Remes<sup>4</sup>, Richard Rosenquist<sup>8</sup>, Anton W. Langerak<sup>9</sup>, Ludo M. Evers<sup>3</sup>, Thorsten Zenz<sup>10</sup>, Jan Walewski<sup>11</sup>, Marinus H. J. van Oers<sup>3</sup>, Christian H. Geisler<sup>2</sup>, Arnon P. Kater<sup>3</sup>, and Carsten U. Niemann<sup>2</sup>, *on behalf of the HOVON68 trial group*. Favorable outcome for high-risk CLL belonging to the B-cell receptor stereotyped subset #2: results from the HOVON68 trial. Submitted 2018
6. Jarmo Ritari<sup>1</sup>, Kati Hyvärinen<sup>1</sup>, Satu Koskela<sup>1</sup>, Riitta Niittyvuopio<sup>2</sup>, Anne Nihtinen<sup>2</sup>, Urpu Salmenniemi<sup>3</sup>, Mervi Putkonen<sup>3</sup>, Liisa Volin<sup>2</sup>, Tony Kwan<sup>4</sup>, Tomi Pastinen<sup>4,5</sup>, Maija Itälä-Remes<sup>3</sup>, Jukka Partanen<sup>1</sup>. Genome-wide analysis of non-synonymous mismatches in complications of allogeneic hematopoietic stem cell transplantation. Submitted 2018.

### ***Manuscripts in preparation***

1. Chalandon Y, Sbianchi G, Hoek J, Apperley J, **Itälä-Remes M**, Markiewicz M, Russell N, Sengeloev H, Aljurf M, Malladi R, Remenyi P, de Groot M, Snowden J, Socie G, Ljungman P, Schaap M, Lenhoff S, Passweg J, Maertens J, Cornelissen JJ, Yakoub-Agha I, Ayuk F, Afanasyev B, Olavarria E, Kröger N. Allogeneic hematopoietic stem cell transplantation in patients with CML-CP in the era of third generation tyrosine kinase inhibitors: a study by the CMWP of the EBMT
2. Potter V, Wang J, Ehninger G, Auyk F, Koster L, Finke J, Beelen D, Socie G, Ganser A, Sengeloev H, Labussiere-Wallet H, **Itälä-Remes M**, de Wreede L, Gascon M, Jindra P, Mufti G, Tischer J, Koe Y, Arat M, Bornhäuser M, Christopheit M, Bertz H, Steckel N-K, Kröger N, Robin M. Comparison of sequential versus myeloablative, reduced intensity and non-myeloablative conditioning for patients with myelodysplastic syndrome: an analysis of the CMWP of the EBMT
3. Gran Charlotte, Kröger Nicolaus et al. Treosulfan conditioning for allogeneic hematopoietic stem cell transplantation in multiple myeloma, while reducing non-relapse mortality, still have a high incidence of relapse.
4. Christoph Schmid, Myriam Labopin, Gerard Socié, Maija Itälä-Remes, Didier Blaise, Ibrahim Yakoub-Agha, Noel Milpied, Jan Cornelissen, Arnold Ganser, Dietrich Beelen, Hélène Labussière-Wallet, Jakob Passweg, Bipin Savani, Mohamad Mohty and Arnon Nagler on behalf of the ALWP of EBMT. Secondary AML is an independent risk factor for outcome after SCT in first complete remission - A registry-based comparison to de novo AML on behalf of the EBMT Acute Leukemia Working Party.